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ABSTRACT 
Background: There are several options available for aortic valve replacement (AVR), with few 
comparative reports in the literature. The optimal choice for AVR in each age group is not clear.  
Objectives: Our study aims to report and compare outcomes after AVR in the young using data 
from a national database. 
Methods: AVR procedures were compared after advanced matching, both in pairs and in a 3-
way manner, using a Bayesian dynamic survival model.  
Results: A total of 1,501 patients who underwent AVR in the UK between 2000 and 2012 were 
included. Of these, 47.8% had a Ross procedure, 37.8% a mechanical AVR, 10.9% a 
bioprosthesis AVR and 3.5% a homograft AVR, with Ross patients being significantly younger 
when compared to the other groups. Overall survival at 12 years was 94.6%. In children, the 
Ross procedure had a 12.7% higher event free probability (death or any reintervention) at 10 
years when compared to mechanical AVR (p = 0.05). We also compared all procedures except 
the homograft in a matched population of young adults, where the bioprosthesis had the lowest 
event-free probability of 78.8%, followed by comparable results in mechanical AVR and Ross, 
with 86.3% and 89.6%, respectively. Younger age was associated with mortality and pulmonary 
reintervention in the Ross group and with aortic reintervention in the mechanical AVR. Out of all 
3 options only the patients undergoing the Ross procedure approached the survival of the general 
population.  
Conclusions: AVR in the young achieves good results, with the Ross being overall better suited 
for this age group, especially in children. Although freedom from aortic valve reintervention is 
superior after the Ross procedure, the need for homograft reinterventions is an issue to take into 
account. All methods have advantages and limitations, with reinterventions being an issue in the 
long term for all, more crucially in smaller children.  
 
Key words: aortic valve disease; Ross procedure; aortic valve replacement; congenital heart 
disease 
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VSD – ventricular septal defect 
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Young patients with aortic valve (AoV) disease can be palliated by transcatheter or 
surgical methods but most will eventually require an aortic valve replacement (AVR). There are 
several options available for children and young adults: mechanical (M-AVR), pulmonary 
autograft or the Ross procedure (R-AVR), biological heterograft (B-AVR) and homograft valves 
(H-AVR). Each has its uses and limitations and, more importantly, no option is perfect. There is a 
set of qualities an aortic valve substitute should have, and presently there is no choice that can 
achieve them all, with many factors influencing the choice and long term results of an AVR. Data 
on outcomes vary, with few national and even fewer comparative studies. Multicenter studies 
would be best suited to describe and compare modern results. The objective of the current study 
is to describe early and long-term survival and freedom from reintervention in a national 
population of consecutive, unselected young patients, to compare the results of the main types of 
AVR in appropriately matched populations and to identify factors influencing outcome for each 
procedure type. 
Methods 
The National Congenital Heart Disease Audit (NCHDA) collects validated key data on 
cardiac procedures from all the UK units, using a mechanism for data capture, cleaning and 
validation similar to that for adult cardiac surgery (1). 
Using linkage with census records at the Office of National Statistics (ONS), the audit 
database publicly reports survival rates at 30 days and 1 year following the index procedure 
online. Linkage with survival registries of Northern Ireland and Scotland cannot be done 
consistently with the patient’s personal identification number, while a minority of them either 
have errors in their social data or are foreign. This resulted in 10.6% of patients not having data 
beyond 30 days, due to administrative reasons.The remaining patients have long term follow-up 
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from either the ONS or from other entries in the database. 
Indications for each operation were established by multidisciplinary teams at each center. 
Diagnosis and procedure codes from the European Pediatric Cardiac Code Short List are used for 
reporting of data. The quality index for key procedure fields is above 95%. The completeness 
and accuracy of non-critical data fields cannot be estimated without detailed patient-level data 
from each center, but there is no indication of systematic, persistent errors in reporting. The need 
for patient-level consent to participate in this retrospective study was waived by the National 
Institute for Cardiovascular Outcomes Research Board. 
Patient selection 
All available data on patients undergoing an AoV procedure for a congenital cause 
between April 2000 and March 2012 were selected and anonymised. Out of these, 2,767 had an 
AVR. 
We excluded 671 patients who were >40 years old, as we considered that above this age 
degenerative disease is more prevalent. We also excluded those patients with associated complex 
heart abnormalities (n = 193), rheumatic fever (n = 15), unclassified AVR procedures (n = 313) 
and unknown age at index procedure (n = 74). The excluded complex heart abnormalities were: 
univentricular conditions, valvar atresias, interrupted aortic arch, atrioventricular septal defect, 
transposition of great arteries, common arterial trunk, Fallot-type defects, severe vascular 
abnormalities (e.g., major aorto-pulmonary collaterals) and atrial isomerism. Unclassified AVR 
procedures were due to errors in reporting, i.e. using a general “Aortic valve replacement” code. 
Reinterventions were defined as either reoperations or catheter based procedures related 
to the aortic valve or root and to the pulmonary valve and right ventricle outflow tract (RVOT) 
for the Ross operation group. Not included were early reinterventions (within 30 days, 
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considered connected to intraoperative events and not prosthesis durability) and aorta 
dilation/aneurysms repairs which were related to previous conditions (e.g., Marfan syndrome). 
When comparing the procedures, separate calculations were made for AoV reinterventions and 
any reinterventions, due to the fact that the Ross procedure is at risk of both AoV and RVOT 
reinterventions.  This was done to ensure that the comparisons between procedures can be 
properly interpreted, with both AoV and overall freedom from reintervention comparisons. 
Statistical Analysis 
Frequencies are given as absolute numbers and percentages, continuous values as median 
(inter-quartile range). Short term mortality is calculated based on 30 day life status. Population 
characteristics were compared using the Mann-WhitneyU test, Kruskall Wallis test, t-test and the 
Fisher exact test. Estimates of long term outcomes in Table 3 and also for neonates and H-AVR 
are made with the Kaplan Meier method using mortality (all cause) and reintervention, death 
being censoring for reintervention. Risk factor analysis for the B-AVR and H-AVR groups was 
performed using the log-rank test and Cox proportional hazards regression. 
In addition to aggregate, non-parametric analysis of short-term and long-term survival 
rates, we used a Bayesian dynamic survival model to perform Variable Importance Analysis and 
Procedure Comparison Analysis (2). The resulting dynamic hazard ratios allowed us to 
differentiate early-phase and late-phase impact of variables on mortality and reintervention, 
providing a measure of significance for the trend in the hazard ratio, if any is present. For 
Procedure Comparison Analysis (2-way and 3-way), a combination of propensity score 
matching, restriction matching, and stochastic augmentation was used to implement matching 
without replacement and ensure balanced distribution of age, gender, aortic disease type, and 
subaortic stenosis across different procedure types (3). Separate models for mortality, AoV 
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reintervention and overall reintervention were built, treating death and reintervention as 
competing, and combined using the cause-specific hazard approach to competing-risk analysis. 
R-AVR versus M-AVR comparison was done after matching as described above, adjusting by 
age, AVR type and interaction between the 2. The other comparisons are done adjusting only by 
AVR type. Variable importance analysis used a multivariable model including age (continous), 
age group, gender, aortic disease type, mitral disease, coarctation, subaortic stenosis, genetic 
syndrome, mitral valve procedure, coarctation repair, subaortic stenosis repair at index, with 
hypothetical patient profiles being used to provide context for each plot. Model coefficients are 
estimated using Monte Carlo Markov chain sampling of posterior distribution, and hazard ratios 
are plotted vs. follow-up time (dynamic hazard ratios), with corresponding, sampled-based p-
values indicating their significance. Bayesian Lasso shrinkage was used as a built-in variable 
selection mechanism to minimize the degrees-of-freedom problem in light of increased model 
parameters. Missing data regarding aortic disease type were not imputed, as not enough data was 
available to ensure this is done properly. Instead a separate category was created 
(“Undetermined”). 
For further methodological details in the Online Appendix. Statistical analyses were 
done with STATA/IC 11.2 (StataCorp LP, College Station, Texas) and R version 3.1 (R Core 
Team, 2015). 
Results 
A total 1,501 patients <40 years who underwent an AVR procedure were included in the 
analysis. Out of these, 718 (47.8%) had R-AVR, 567 (37.8%) had M-AVR, 163 (10.9%) had B-
AVR and 53 (3.5%) had H-AVR. Table 1 shows data completeness and Table 2 demographic, 
clinical and procedure-related data. From the 289 patients (19.2%) with no specific data on AoV 
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hemodynamics, 86 (29.7%) had only bicuspid morphology noted, as some centers do not 
systematically report aortic disease type when a bicuspid valve is seen, assuming there will be 
mixed aortic disease. 
There were significant differences in age and gender between groups, most notably R-
AVR patients being younger than in the other 3 groups (R-AVR mean age 13.7 years vs M-AVR 
25.5, B-AVR 25.7 and H-AVR 18.8, p<0.001, Figure 1), while more males were operated using 
M-AVR rather B-AVR (30.9% vs 21.3%, p<0.001). 
Significantly fewer patients with documented aortic regurgitation had R-AVR when 
compared to the rest of the group (R-AVR 23% vs 32.7% otherwise, p<0.001). No significant 
differences in patient distribution by lesion type were observed between the remaining 3 groups. 
Out of the four main associated abnormalities and corresponding concomitant procedures (Table 
2) there were several significant differences between the R-AVR group and the remainder of the 
patients: subaortic stenosis had a higher frequency in the R-AVR group, with 16.2% vs 8.3% 
(p<0.001) as did the procedure to correct it at index, 12% vs 5.2% (p<0.001). Also, slightly 
fewer R-AVR patients had a VSD (4.3% vs 8.9%, p<0.001) or a VSD closure at index (0.7% vs 
3.2%, p=0.001). No differences in mitral valve disease or aortic coarctation prevalence were 
found between groups. 
The short and long term outcome estimates are shown in Table 3. The best results were 
achieved in the R-AVR group, with 97.3% survival and 94.7% freedom from aortic 
reintervention at 12 years. The H-AVR group had a poor freedom from reintervention, with 
73.8% at 5 years and 59.8% at 12 years, but survival was comparable with the other 3 groups, 
being 93.4% at 12 years. 
Infants and children 
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The majority of infants and neonates, 55/61, underwent R-AVR. Overall, the 30-day and 
1 year mortality were 10.5% and 14.3%, respectively; one patient died beyond 1 year. Overall 
freedom from aortic reintervention is 84.7%, CI[67.9-93.2] and freedom from pulmonary valve 
and RVOT reintervention for the Ross operation is 72.5%, CI[52.5-85.2]. 
In children between 1 year and 16 years old (n=568), the 2 most-used AVR options are R-
AVR (77.2%) and M-AVR (17.3%). We examined them after matching using the Procedure 
Comparison Analysis (Figure 2). Median M-AVR to R-AVR hazard ratio (HR) for death starts at 
4.8 after the procedure (p=0.09, panel A) and in 10 years decreases to 2.7 (p=0.2). However, this 
decline is not statistically significant (p-value for difference in HR is 0.65). The difference in 
cumulative incidence of death between R-AVR and M-AVR is 5.1% at 10 years (M-AVR being 
higher, p=0.10). In terms of AoV reintervention risk, M-AVR to R-AVR HR starts at 2.8 (p=0.15) 
and reaches 2.6 at 10 years (p=0.08), without a significant dynamic trend (Panel B). The 
difference in cumulative incidence of AoV reintervention between R-AVR and M-AVR is 9.9% 
at 10 years (M-AVR being higher, p=0.07). When considering all reinterventions (Panel C), the 
M-AVR to R-AVR HR starts at 2.2 (p=0.21) and reaches 1.9 at 10 years (p=0.21), with a 
difference in cumulative incidence of 7.7% at 10 years (p=0.19). Finally, overall event-free 
probability for R-AVR is 12.7% higher than M-AVR at 10 years (p=0.05, panel D). 
Ten children underwent B-AVR and 21 had H-AVR with no deaths during follow-up. In 
terms of AoV reintervention, 1/10 with B-AVR required a reintervention at 2.7 years (actuarial 
freedom from reintervention 80%), while 7/21 from the H-AVR group did (actuarial freedom 
from reintervention 38.4%). No other comparisons were possible between these groups and the 
other 2 in this age due to small sample sizes. 
Young adults 
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Out of the 872 patients between 16 and 40 years old, 224 (25.7%) had R-AVR, 468 
(53.7%) had M-AVR, 152 (17.4%) B-AVR and 28 (3.2%) H-AVR. All 3 main choices for AVR 
are used in young adults so we were able to analyze outcomes both in a 3-way comparison and 
also in pairs. This was necessary due to the particular overlapping pattern in age distribution 
(Figure 1), which led to different ends of this age group being matched in different comparisons 
(e.g. younger for R-AVR vs M-AVR, older for M-AVR vs B-AVR). 
Ross operation vs Mechanical prosthesis vs Bioprosthesis: Mortality and reintervention 
are highest in the B-AVR group, followed by M-AVR, being lowest in the R-AVR group, with a 
10-year event-free probability after matching of 78.8% (B-AVR), 86.3% (M-AVR) and 89.6% 
(R-AVR) respectively (Figure 3). 
Ross operation vs Mechanical prosthesis (Figure 4): After matching, M-AVR has a 
higher hazard for both death and reintervention but not statistically significant, with the 
exception of early mortality where HR is 3.0, p=0.09 (panels A,B,C). Overall, this does not 
translate into significant differences in the event free probabilities (panel D). Similar to children, 
we do not see significant dynamic trends for the hazard ratio. 
Ross operation vs Bioprosthesis (Figure 5): In the matched group comparison, The 
mortality risk is significantly higher for B-AVR within the first 5 years after the index, the 
median HR starting at 5.4 (p=0.04) and reaching 2.5 at 10 years (p=0.12), panel A. The risk for 
AoV reintervention was significantly higher for the B-AVR group, with a HR starting at 2.2 early 
after the index, becoming statistically significant at around 1 year of follow-up and reaching 4.1 
at 10 years (p=0.01), panel B. When considering overall reintervention risks, we see the same 
pattern (panel C), albeit with smaller HR values. These differences are reflected in the higher 
event free probability for the R-AVR, panel D. No significant time-dependence for death or 
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reintervention hazard ratio was found. 
Mechanical prosthesis vs Bioprosthesis (Figure 6): While death hazard is similar in B-
AVR and M-AVR matched groups (Panel A), reintervention hazard becomes higher in B-AVR 
starting from 5 years after the index, with 10-year HR being 2.3 (p=0.12, Panel B). 
Correspondingly, cumulative incidence of reintervention is 8.8% higher in B-AVR compared to 
M-AVR (p=0.12, Panel D). 
Risk factors associated with AVR 
Ross procedure: While the risk of aortic reintervention shows no statistically-significant 
difference across age groups, mortality risk is higher for neonates and infants compared to 
children and young adults, especially within the early phase of the first 3 years of follow-up 
(Figure 7A). AoV regurgitation is associated with higher reintervention risk, compared to mixed 
disease and stenosis (Figure 7B). The risk becomes statistically significant shortly after surgery 
but does not exhibit a dynamic behavior. Age appears to have a steady impact on pulmonary 
reintervention: the younger the patient, the higher the risk (Figure 7C). The hazard ratios are 
steady and statistically significant over time. This is in contrast to the early-phase impact of age 
on mortality risk (Figure 7A). Time-independence of age hazard ratio for pulmonary 
reintervention suggests that the increased risk with younger age is related to the procedure 
performed and is not influenced by time-varying factors. We did not find gender to be a predictor 
of pulmonary reintervention or death. 
Mechanical prosthesis: No predictors for mortality were found in this group. Younger age 
was associated with significantly higher hazard and cumulative incidence for aortic 
reintervention (Figure 7D). 
Biopsrosthesis: Mitral valve abnormalities (HR=7.1, p=0.014, CI [1.4-35.9]) and 
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subaortic stenosis (HR=6.3, p=0.025, CI [1.2-31.5]) were associated with higher mortality risk in 
this group but we were limited to univariable analysis. No predictors for mortality were found. 
Homograft: A total of 3/53 patients died in this group, 2 of them also being the only 2 
neonates operated with a homograft AVR, pointing to age under 30 days being a risk factor. 
Younger age was also identified as a risk for aortic reintervention (univariate analysis 
HR=1.08/year, p=0.02, CI [1.01-1.15]). 
Comparison with the matched general population 
Survival after R-AVR, B-AVR and M-AVR was compared with that of the general 
population, with R-AVR being the only method having a survival pattern closely similar to that 
of the general population. The method, results and discussions are available (Online Appendix).  
Discussion 
This study shows that the prevalence of various AVR options is in keeping with what is 
known and expected in children and young adults (Central Illustration). The Ross procedure is 
the most common option in children due to its growth potential but its utilization decreases in 
young adults. All valves achieved good survival, the lowest 12-year estimate being for M-AVR at 
90.6%. The 12-year freedom from reintervention is over 90% for R-AVR and M-AVR but only 
75% and 59.5% for B-AVR and H-AVR respectively (Table 3). 
More insight was gained by detailed subgroup analyses, in which R-AVR emerged as 
overall superior, at worst comparable to M-AVR in young adults. In a separate analysis 
examining UK trends we found that the Ross procedure has excellent results in young patients 
but, curiously, its usage is gradually decreasing over time, the main competitors being balloon 
valvoplasty in children and M-AVR in young adults (4). 
Most of the data available on long term outcomes in AVR in children and young adults 
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comes from single center studies, with just a few multicenter reports and even fewer comparative 
ones. The German-Dutch registry reports excellent results with the Ross procedure in older 
patients (5), while the Society of Thoracic Surgeons reports short term results from a national 
database in infants (6). Published data on outcomes after each individual AVR type is readily 
available, but patient age, clinical status, and methodology vary widely. Comparative studies in 
the young are scarce and confronted with the same limitations we encountered, specifically 
differences in patient characteristics. No randomized AVR studies were performed in children 
and only a few were done in adults. A review of modern literature on AVR in the young shows a 
particular interest in the Ross procedure, in some reports survival being comparable with that of 
the general adult population (7-9). Careful patient selection and technical modifications are most 
likely responsible for the improved results (5,9,10). This naturally leads to the question: is the 
Ross procedure the gold standard in AVR in the young? And if so, where do we stand in regards 
to the other 3 options? 
Neonates and infants 
In our study the majority of them  underwent R-AVR. But the Ross operation is not 
always seen as first choice for small children. Surgical or transcather repair are sometimes 
preferred to postpone AVR, on the grounds that palliation can achieve good results (11,12), while 
AVR mortality in these patients is high, ranging from 15-50% (12-14). We have seen a lower 
early mortality in this age group (10%) but still we found that age under 1 year is a risk factor in 
the R-AVR overall. The lower mortality may be related to excluding patients with complex 
associated defects, like interrupted arch, specifically found to be a risk factor by others.(6, 15) 
Hickey et al report high mortality in neonates and infants undergoing a Ross procedure, but these 
patients had either critical stenosis or a failed previous repair, the results being otherwise 
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acceptable for patients older than 3 months presenting electively (10). In other words performing 
a Ross procedure in unfavorable circumstances may lead to unfavorable results, but these are 
situations where alternatives are limited. 
We found that age<1 year was a significant risk factor for pulmonary conduit 
reintervention, as previously reported, in keeping with the notion that a small conduit is rapidly 
outgrown (5). Examining the best treatment sequence in small children (including palliation by 
valve repair and balloon dilation) was beyond the scope of this paper, but the small number of 
AVRs in infants nationally suggests this option is considered after all other treatment paths are 
exhausted. 
Children 
It has previously been shown that hetero- and homografts are not suitable in the long term 
in the pediatric population and should be used with caution. Bioprosthesis valves have been 
associated with a risk of rapid deterioration and explantation (16), or even catastrophic early 
failure (17). Results achieved with homograft valves have been variable, but a high incidence of 
reoperation has been reported (16,18). This was mirrored in our group by the majority of children 
reiceiving either a Ross autograft or a mechanical valve. Compared to R-AVR, M-AVR has 
higher mortality, especially in the early phase, and slightly higher aortic reintervention risks. 
Taking into consideration the RVOT reinterventions, it results in a 12.7% difference in event-free 
probability at 10 years in favour of the Ross (Figure 2). Alsoufi et al. also found a significantly 
higher mortality risk after M-AVR, but a higher risk of aortic reintervention in the Ross group, 
noting that patients with rheumatic disease were included and found to be at increased risk for 
reintervention (19). Ruzmetov reported a single center series with similar results as our national 
audit (16). In a study with 10 years of follow-up Lupinetti also found that mechanical AVR in 
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children had worse results when compared to autograft/allograft (20).  
Young adults 
In young adults, all main 3 choices of valves are available, patients receiving a Ross 
autograft being the youngest in our group, those having a mechanical AVR the oldest, with the 
bioprosthetic in between (Figure 1). In a 3-way matched comparison, we found that biological 
valves are associated with the worst results, followed by mechanical valves and Ross with 
comparable results, albeit slightly better for the latter (Figure 3). These results persist in pairwise 
comparisons, which broaden the matched groups depending on the particular overlap in age 
(Figures 4-6). 
Comparing the Ross procedure and mechanical AVR we found a slightly higher mortality 
and aortic reintervention risk in M-AVR, but overall event free probabilities are comparable after 
considering the RVOT reinterventions (Figure 4). Mokhles compared the R-AVR and optimally 
anticoagulated M-AVR in propensity score matched groups for the non-elderly adult population, 
finding no differences in mortality and significantly higher aortic reintervention rates in the Ross 
group (21). There are several differences between this study and ours: our patients are younger, 
we did not use propensity matching but rather a composite approach, and finally our M-AVR 
patients were not under highly specialized anticoagulation but under real life conditions when 
compliance is variable. 
Few reports compare the Ross procedure with the bioprosthetic valve in the young. 
Ruzmetov reported better survival with Ross at 15 years (91% vs 84%) (but children were also 
included and noted to have higher mortality), comparable freedom from aortic reintervention, 
and higher risk of AoV explantation in the bioprosthesis group (22). We found no differences in 
long term mortality in our matched groups (the difference being we compared only young 
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adults), but we did find a higher risk for AoV  reintervention in the B-AVR group, especially 
starting after 2 years of follow-up (Figure 5). 
Comparing the mechanical to bioprosthetic valves in matched young adults groups, we  
found modest differences in mortality and aortic reintervention, the risks being slighly higher in 
the latter (Figure 6). Ruel examined mechanical prostheses with biological (heterograft and 
homograft) in a population of young adults and found comparable results in long term mortality 
but significantly worse freedom from reintervention in the biological valve group (worse in the 
heterograft vs homograft). In addition there was a lower overall quality of life in the mechanical 
group (23). Interestingly, when patients of similar ages are compared in our study, the differences 
are not as striking as previosly reported, but this might also be due to the small sample size. The 
results suggest that B-AVR remains a reasonable option for young adults, particularly in keen 
patients such as women contemplating pregnancy. 
Risk factors associated with AVR 
Our data originated in a procedure-based audit, therefore we had few other variables to 
consider as predictors. The focus became age, valve disease type and concomitant defects and 
procedures, also looking into the dynamic effect they might have during follow-up. The choice to 
apply dynamic survival analysis was influenced by the belief that some key drivers of outcome 
may not have the same impact in various stages of follow-up. Our results highlighted 3 cases of 
age influencing outcome: mortality risk and pulmonary reintervention for the Ross procedure, 
and aortic reintervention for M-AVR (Figure 7). In the first case, we saw a strong early-phase 
hazard for neonates and infants compared to children and young adults, consistent with the more 
severe clinical condition associated with presentation at earlier ages. In the other 2 cases, an 
increased hazard for younger patients was noted which lasted long into follow-up. This is 
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consistent with an inherently higher risk due to the initial surgery. A dynamic model allowed us 
to differentiate these 2 patterns and hypothesize about the different root-causes of each. Of 
course an alternative is to build independent models for different age groups to allow for 
arbitrary hazard ratios between them, but this would not be as efficient a use of data as building a 
single model that contains all age groups. 
In summary, the U.K. national dataset allowed complete procedural and survival follow 
up for AVR carried out in the young. The Ross procedure has multiple advantages which seem to 
extend beyond childhood, being superior to other AVR types when compared in matched groups, 
especially in children, but all prostheses perform reasonably well overall. The study is limited by 
absence of more clinical data such as operative timing and echocardiography, also by relatively 
short follow-up. Future planned research revolves around linkage with other UK valve registries 
to obtain longer follow up as well as examining the role of surgical and balloon valvoplasty in 
delaying AVR. Cost and quality of life analyses would similarly add to the quest for finding the 
most advantageous valve substitutes for individual patients.  
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Perspectives 
Competency in Patient Care and Procedural Skills: While most methods of aortic valve 
replacement in children and young adults are associated with good outcomes, the Ross procedure 
achieves better survival than other valve replacement options, but is associated with more 
frequent need for subsequent interventions. 
Translational Outlook: Longer follow-up studies may identify high and low-risk subgroups and 
better inform selection of optimum approaches for individual patients. 
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FIGURE LEGENDS 
Central Illustration: Aortic valve replacement and the Ross operation in children and 
young adults. Dynamic changes of risk of mortality or reintervention during follow up period 
after AVR operation by the procedure types and the age groups. Risk of both mortality and 
reintervention decrease with the patient age and increase during follow-up. The overall increase 
of risk differs depending on the AVR procedure type and the speed of increase in risk during the 
various stages of follow up time is not proportional across the AVR types. Distances and the 
levels of increase in risk are drawn schematically and, therefore, are not precise.  
Figure 1: Age distribution histogram by procedure type. Columns represent fraction from 
total for 1 year wide bins. Continous line represents the kernel density. 
Figure 2: Comparison of long term outcomes between Ross AVR and mechanical AVR in 
children using matched groups. Hazard functions (top row) and dynamic hazard ratios/event 
free probability differences (bottom row with confidence intervals) are shown, derived from a 
Bayesian Mixture Survival Model using the additive mixture of 2 Weibull hazards. Samples are 
matched by gender, age, aortic disease type, association of subaortic stenosis, using a stochastic 
algorithm with propensity score matching. The model was adjusted by age group and the 
interaction between age group and AVR type was included.  
Figure 3: Comparison of long term outcomes between the Ross operation, mechanical AVR 
and bioprosthesis for young adults (16-40 years old). Confidence bands are not included to 
avoid clutter. These are unadjusted event curves after matching using a 3-way composite 
algorithm (described in methods).  
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Figure 4: Comparison of long term outcomes between Ross AVR and mechanical AVR in 
young adults using matched groups. See caption of Figure 2 for details on panel rows, model 
and matching. The model is unadjusted. 
Figure 5: Comparison of long term outcomes between the Ross operation and bioprosthesis 
AVR in young adults using matched groups. See caption of Figure 2 for details on panel rows, 
model and matching.  The model is unadjusted. 
Figure 6: Comparison of the mechanical AVR and biopsothesis in young adults in terms of 
long term outcomes in matched groups. See caption of Figure 2 for details on panel rows, 
model and matching.  The model is unadjusted. 
Figure 7: Risk factors for death or reintervention in Ross and Mechanical AVR. Hazard 
functions are derived from multivariable bayesian mixture survival models (separate for Ross 
and mechanical AVR), using the additive mixture of 2 Weibull hazards, adjusted by age 
(continous), age group, gender, aortic disease type, mitral disease, coarctation, subaortic stenosis, 
genetic syndrome, mitral valve procedure, coarctation repair, subaortic stenosis repair at index. 
The mid-point of each age group was chosen as the age of its corresponding hypothetical patient, 
while the rest of the categorical variables were set as zero.  Panel A: Impact of age on mortality 
risk for Ross procedure. Panel B: Impact of aortic disease type on reintervention risk for Ross 
procedure. Panel C: Impact of age on risk of pulmonary reintervention for Ross procedure. 
Panel D: Impact of age on reintervention risk for the Mechanical AVR procedure in young 
adults. 
Dynamic hazard ratios, CI differences, event free probability differences and their corresponding 
p values can be seen in the Online Appendix 
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Table 1. Data Completeness  
National Health System ID 100% 
Aortic Valve Hemodynamics 80.7%
Diagnosis 97.9%
Weight 92.8%
Sternotomy number 79.8%
Hospitalization period 97.5%
Discharge status 99.9%
30 day status 89.3%
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Table  2. Patients characteristics and procedure data by aortic valve replacement (AVR) type
 Total Ross 
autograft 
Mechanical 
AVR 
Bioprosthetic 
AVR 
Homograft 
AVR 
Patients (n) 1501 718 567 163 53 
Age (y)      
Median (IQR) 17.8 
(12.1-
28.7) 
13.1 (7.5-
17.0) 
26.3 (17.6-
33.6) 
24.8 (20.1-
31.0) 
16.4 (12.0- 
27.6) 
Gender (n, %)      
Male 1091 
(72.7) 
514 (71.6) 446 (78.7) 104 (63.8) 27 (51.0) 
Age group (n, %)      
Neonate (<30 days) 8 (0.5) 6 (0.9) 0 (0) 0 (0) 2 (3.8) 
Infant (1-12 months) 53 (3.5) 49 (6.8) 1 (0.2) 1 (0.6) 2 (3.8) 
Child (1-16 years) 568 
(37.9) 
439 (61.1) 98 (17.3) 10 (6.1) 21 (39.6) 
Young adult (16-40 
years) 
872 
(58.1) 
224 (31.2) 468 (82.5) 152 (93.3) 28 (52.8) 
Follow-up (y)      
Median (IQR) 5.3 (2.1-
8.6) 
6.6 (2.5-
9.6) 
4.7 (1.8-7.5) 3.5 (2.0-5.6) 5.6 (1.1- 
8.5) 
Aortic valve disease, (n, 
%) 
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Stenosis 492 
(32.8) 
268 (37.3) 148 (26.1) 25 (15.3) 8 (15.1) 
Regurgitation 421 
(28.0) 
165 (23.0) 181 (31.9) 58 (35.6) 17 (32.1) 
Mixed 299 
(19.9) 
190 (26.5) 76 (13.4) 59 (36.2) 17 (32.1) 
Unkown 289 
(19.3) 
95 (13.2) 162 (28.6) 21 (12.9) 11 (20.7) 
Marfan Syndrome (n, %) 41 (2.7) 0 (0) 37 (6.5) 1 (0.6) 3(5.7) 
Concomitant procedures      
Mitral valve 58 (3.9) 22 (3.1) 29 (5.1) 5 (3.1) 2 (3.8) 
Subaortic 127 (8.5) 86 (12.0) 32 (5.6) 5 (3.1) 4 (7.5) 
Ventricular septal defect 
repair 
30 (2.0) 5 (0.7) 15 (2.6) 7 (4.3) 3. (5.7) 
Coarctation/Hypoplasia 
repair 
18 (1.2) 7 (1.0) 8 (1.4) 3 (1.8) 0 (0) 
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Table 3. Survival and freedom from reintervention by aortic valve repair (AVR) type 
 Overall Ross 
procedure 
Mechanical 
AVR 
Bioprosthetic 
AVR 
Homograft 
AVR 
Patients n=1501 n=718 n=567 n=163 n=53 
Survival (%) 
30-day 98.4 98.9 98.0 97.4 97.9 
5 years 
estimate 
[95% CI] 
96.2 
[95.0-97.2] 
97.6 
[96.0-98.6] 
95.0 
 [92.4-96.7] 
94.9 
[89.3-97.6] 
93.4 
[81.0-97.8] 
12 years 
estimate 
[95% CI] 
94.6 
[92.8-95.9] 
97.3 
[95.6-98.4] 
90.6 
[85.8-93.9] 
92.6 
[84.2-96.7] 
93.4 
[81.0-97.8] 
Freedom  from aortic reintervention (%) 
5 years 
estimate 
[95% CI] 
96.0 
[94.6-97.0] 
97.2 
[95.5-98.3] 
96.2 
[93.7-97.6] 
94.3 
[86.0-97.7] 
73.8 
[55.3-85.6] 
12 years 
estimate 
[95% CI] 
90.4 
[87.1-93.0] 
94.7 
[91.7-96.6] 
91.8 
[86.8-94.9] 
75.0 
[53.2-87.8] 
59.5 
[37.9-75.7] 
Freedom from pulmonary valve reintervention (%) 
5 years 
estimate 
[95% CI] 
 98.0  
[96.4-98.9] 
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12 years 
estimate 
[95% CI] 
 91.1 
[87.3-93.8] 
   
Unadjusted Kaplan Meier estimated values with death and reintervention (aortic and 
pulmonary) as failures; death is censoring for reintervention.  
 








APPENDIX A: Methodological Details 
In this section, we provide methodological details pertaining to various steps in the data 
preparation and analysis. 
Statistical Matching 
For Procedure Comparison Analysis, we used a custom matching algorithm to ensure a 
balanced distribution of gender, age, aortic disease type, and subaortic stenosis across 
observations for different procedures. This algorithm relaxed a requirement in common 
matching algorithms such as Propensity Score Matching, that the matched dataset must 
contain an equal number of observations from each treatment group. This requirement would 
lead to two equally-undesirable outcomes: small matched datasets or repeated observations. 
The first outcome is especially unattractive since our dataset is relatively small, and our 
dynamic survival model doubles the number of degrees of freedom used in the model. The 
second outcome is also unfavorable because duplicate observations can invalidate the 
outcome of a cross-validation-based approach for selecting the shrinkage parameters in the 
survival model. A second shortcoming of the existing matching algorithms is that they 
deterministically select a fixed subset of the observations in the matched data set; in other 
words, certain observations are never used in the remainder of the analysis. Again, given the 
small number of observations in our problem, we viewed this shortcoming as a critical one. 
The matching algorithm constructs and combines 2-D histograms of gender and age for each 
treatment group into a target profile, scaled up or down for each treatment to maximize 
sample size while retaining relative contribution from each histogram cell. Random sub-
sampling of observations within each cell is followed by application of t-test or chi-squared 
test to ensure balanced distribution of age and gender in matched sets. We considered 
Kolmogorov-Smirnov test (KS), which assesses balance of two distributions not just in terms 
of their mean, as in t-test. However, we preferred t-test and chi-squared test for two reasons: 
First, KS's generalization to multiple distributions is not a fully-established subject. Secondly, 
in the context of regression modeling, the more detailed matching achieved by KS is 
unnecessary and can lead to excessively small matched data sets. To ensure balance with 
regards to aortic disease type and subaortic stenosis, we applied similar tests to each output 
of the algorithm and accept only those that pass the test. We set a threshold of 0.25 for the 
p-value of all statistical tests in this paper, although actual p-value for matched datasets was 
generally much higher. 
Bayesian Dynamic Survival Model 
We used the R package BayesMixSurv – co-developed by two of the authors of this paper – 
to analyze the data. This package builds a Bayesian dynamic survival model with Lasso 
shrinkage (using Laplace prior on coefficients of each component), using an additive mixture 
of two hazard functions, each of which corresponds to a Weibull distribution for the event 
density function with a different shape parameter.  While each hazard component consists of 
the usual product of a baseline hazard function and the exponential regression component, 
total hazard does not lead to a proportional hazard model. As such, hazard ratio for a 
variable is both time dependent and 'context-dependent'. In other words, the incremental 
hazard due to a change in the value of a variable depends not only on time, but also on the 
value of other variables. In our case, context-dependence was weak due to the presence of 
few statistically-significant variables. Yet, when in using BayesMixSurv we must always 
report the context variables when discussing the hazard ratio for a focus variable. 
Model estimation as well as prediction is done in a Bayesian framework, using Monte Carlo 
Markov Chain sampling of posterior distribution with a univariate slice sampler embedded in 
a Gibbs sampling framework. Shrinkage parameters are tuned via maximization of model 
log-likelihood in a 5-fold cross-validation setting. Lasso shrinkage tends to push the 
coefficients of many variables towards zero, thus playing the role of a built-in variable 
selection algorithm. This is important since it allows us to avoid splitting the data for variable 
selection and model estimation, given the small data set and few events available. 
Sampled-Based Prediction and Analysis 
Since BayesMixSurv is a dynamic model, the hazard ratio for a given variable is not only 
time-dependent, but also 'context-dependent'. Time-dependence means that the hazard ratio 
changes with time, while context-dependence means it changes with values of other 
variables used in the model. In our analysis, since few variables were discovered to have 
significant impact on outcome, context-dependence was of little impact. Nevertheless, all 
results must be viewed in the context of values assumed for other variables. We therefore 
used a 'hypothetical patient' with fixed values of all covariates (except variable whose hazard 
ratio is being studied) when generating our plots. Unless explicitly specified otherwise, this 
hypothetical patient had the following profile (values chosen to best represent the original 
data set): male gender, age of 19.6 years, mixed aortic disease type, all other disease 
indexes: 0. 
Competing-Risk Approach 
Death is considered censoring for reintervention and vice versa. Treating reintervention as 
censoring for death is driven by our belief that reintervention is a sufficiently important event 
that it can significantly alter the mortality risk after its occurrence. We use the cause-specific 
hazard approach to competing-risk analysis, where independent models for each cause 
(death and reintervention here) are built, and then combined together1.  
Procedure Comparison Analysis 
In the first group of BayesMixSurv models, we study the impact of procedure type on 
mortality and reintervention risk. Since we used matched data sets for this analysis, which 
are smaller than the original data, and after the Variable Importance Analysis suggested that 
age is the only significant variable, we decided to perform Procedure Comparison Analysis 
focused on a reduced set of variables. For comparing the Ross procedure and Mechanical 
AVR, we included data for two age groups, children and young adults. In this model, in 
addition to using procedure type as a binary variable (Ross/Mech), we also included age 
group (binary variable) as well as its interaction with procedure type. As an alternative to this 
full interaction within a single model, we could have created two independent models for 
each age group, and the results would be very similar. For pairwise comparison of 
Bioprosthesis to Ross operation or Mechanical AVR, data availability forced us to focus only 
on young adults, and the models included a binary procedure type variable only. Similarly, for 
three-way comparison of Ross/Mech/Bio we focused on young adults, using the output of a 
three-way version of our custom matching algorithm. In all cases, we used 100 instances of 
the stochastic matching algorithm to build BayesMixSurv models, and combined the 
predictions from all 100 trained models to produce a final set of predictions. A sampling-
based approach to estimation and prediction allowed us to perform the combination with 
ease and produce meaningful confidence intervals for the aggregate results. 
Variable Importance Analysis 
This set of analyses used the original data set of 1,501 observations. We focused on the 
Ross and Mechanical AVR for this analysis, given the small size of data and few events for 
Bioprosthesis and Homograft. For the Ross operation, we used the full data set containing all 
4 age groups, while for Mechanical AVR we focused on children and young adults only, since 
there were 0 and 1 observations in neonate and infant category for this category. Again, the 
sampling-based approach facilitated this final blending stage. No matching was necessary 
for this set of analyses, since each model was focused only on one procedure type. 
Survival comparison with the general population 
We compared the UK population-based survival curve with the survival of our patients. To do 
this, we developed an R script to extract mortality probabilities from the life tables of Office of 
National Statistics2 for each patient given their age and gender. Subsequently, we run 1000 
times Monte Carlo (MC) simulations3 to estimate the expected survival of each patient in 
general population. Simulations started from the year of operation and advanced in yearly 
increments. Simulated patient-level events were then aggregated to form Kaplan Meier curve 
which represented the baseline expected survival of the group of patients if they did not have 
the disease and had come from the UK general population. 
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APPENDIX B – comparison with the general population, results and discussion 
Survival for both children and young adults was significantly higher in the simulated group of 
healthy individuals when compared to both types of prostheses, being higher than 99% at 10 
years. Results in the Ross group are similar for both age groups, and closest to that of the 
general population (98.3% vs 99.8% for children and 98.5% vs 99.5% for young adults 
respectively, p<0.001,). M-AVR does not achieve comparable survival with the general 
population in either age group (90.6% vs 99.8% in children and 90.5% vs 99.5% in young 
adults, p<0.001) and neither does B-AVR (90.2% vs 99.7% in children and 92.4% vs 99.5% 
in young adults, p<0.001). 
The main goal of the national audit is to ensure that results in all centers in the UK are both 
good and uniform. When looking at the most common AVR procedures, they do not achieve 
survival similar to that of the general population, as 10-year mortality is very low in the 
healthy young (less than 1%), while being little over 1.5% after the Ross operation, 8.5% 
after the biological AVR and approximately 10% after the mechanical AVR. These results 
underline the need for adjusted expectations for each age group, as achieving the same 
survival after AVR in the young as in healthy individuals is an unreasonable goal, at least at 
present. The fact that the Ross procedure overall closely approaches this goal, while other 
valve replacement types do not, makes it a viable and even desirable option, especially in 
the young. 
 
  
APPENDIX C 
Plots detailing the impact of the age group in mortality and reintervention for the Ross 
procedure, showing hazard, cumulative incidence and event free probability for all four 
groups (Figure 1) and hazard ratio and cumulative incidence difference with their estimated p 
values in two-by-two comparisons (Figures 2-7). Age groups are as follows: 1 – neonates, 2 
– infants, 3 – children, 4 – young adults. 

  
 
APPENDIX D 
Plots detailing the impact of the aortic disease type in mortality and aortic reintervention for 
the Ross procedure, showing hazard, cumulative incidence and event free probability for all 
four groups (Figure 1) and hazard ratio and cumulative incidence difference with their 
estimated p values in two-by-two comparisons (Figures 2-7).  
  
 
  
  
APPENDIX E 
Plots detailing the impact of the aortic disease type in mortality and pulmonary reintervention 
for the Ross procedure, showing hazard, cumulative incidence and event free probability for 
all four groups (Figure 1) and hazard ratio and cumulative incidence difference with their 
estimated p values in two-by-two comparisons (Figures 2-7). Age groups are as follows: 1 – 
neonates, 2 – infants, 3 – children, 4 – young adults. 
 
  
 
  
 
APPENDIX F 
Plots detailing the impact of the age group in mortality and reintervention for the Mechanical 
AVR procedure, showing hazard, cumulative incidence and event free probability for all four 
groups (Figure 1) and hazard ratio and cumulative incidence difference with their estimated p 
values in the two-by-two comparison (Figures 2). Age groups are as follows: 3 – children, 4 – 
young adults. 
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